跳至主要内容
临床试验/NL-OMON42880
NL-OMON42880招募中2 期

Stereotactic MR-guided Adaptive Radiation Therapy (SMART) for localized prostate cancer; a phase II study - SMART localized prostate cancer

Vrije Universiteit Medisch Centrum0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Age of 18 years or older
  • - WHO performance score 0-2
  • - Biopsy proven adenocarcinoma of the prostate
  • - Gleason * 6
  • - Prostate volume * 90 cc on TRUS
  • - T-stage: cT1c-T3b (on MRI and/or endorectal ultrasound)
  • - All patients should be able to undergo MRI scans
  • - No evidence of lymph node or distant metastases on radiological staging
  • - The multidisciplinary team advised external beam radiotherapy treatment
  • - IPSS (International Prostate Symptoms Score) *19
  • - Previous TURP is allowed provided there is at least 8 weeks interval with radiotherapy
  • - The administration of concomitant hormonal therapy is allowed
  • - Ability to provide written informed consent

排除标准

  • - Previous irradiation in the pelvic region
  • - Contra-indications for MRI (see appendix X)

研究者

相似试验